← Explorer/Network

In vitro and in vivo studies to assess the effectiveness of cholestyramine as a binding agent for fumonisins

Solfrizzo M, Visconti A, Avantaggiato G +2 more2001MycopathologiaJournal Article
CardiovascularEndocrine (ADH/ACTH/MSH)GastrointestinalHypothalamic-PituitaryImmune/InnateMusculoskeletalNeurologicalOcularRespiratory/Sinus

Abstract

Several adsorbent materials were tested at I mg/ml for their in vitro capacity to adsorb fumonisin B1(FB1) from aqueous solutions. Cholestyramine showed the best adsorption capacity (85% from a solution containing 200 microg/ml FB1) followed by activated carbon (62% FB1). Bentonite adsorbed only 12% of the toxin from a solution containing 13 microg/ml FB1, while celite was not effective even at the lowest tested FB1 concentration (3.2 microg/ml). Cholestyramine was tested in vivo to evaluate its capacity to reduce the bioavailability of fumonisins (FBs) in rats fed diet contaminated with toxigenic Fusarium verticillioides culture material. Rats were exposed for one week to FBs-free diet, FBs-contaminated diet containing 6 or 20 microg/g FB1 + FB2 and the same FBs-contaminated diet added of 20 mg/g cholestyramine. The increase of sphinganine/sphingosine (SA/SO) ratio in urine and kidney of treated rats was used as specific and sensitive biomarker of fumonisin exposure. The addition of cholestyramine to the FBs-contaminated diets consistently reduced the effect of FBs by reducing significantly (P < 0.05) both urinary and renal SA/SO ratios.

Part of Actinobacteria research, Endotoxins research, Mold & water-damaged buildings research, Mycotoxins research, CIRS biomarkers research · Curated by Lauren Lowenstein, The Biotoxin Lady

Key Biomarkers

Symptom Clusters

Appetite swingsConfusionCoughDifficulty with concentrationExcessive thirstFatigueFrequent urinationHeadacheJoint painLight sensitivityMemory lossMood swingsMuscle achesNight sweatsShortness of breathSinus congestionTingling in extremitiesWord finding difficulty